Loading company
Palvella Therapeutics, Inc.
PVLA · Nasdaq · ·
Next earnings: November 10, 2026
$139.07-0.5%Sep 29 close
- 1M
- -7.3%
- 6M
- +25.7%
- 1Y
- +121.8%
- 5Y
- -69.9%
PVLA · Nasdaq · ·
Next earnings: November 10, 2026
$139.07-0.5%Sep 29 close
Palvella Therapeutics, Inc. is scheduled to report next on November 10, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending September 30, 2024, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2024 | 3 months toSep 30, 2023 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $19.5M | -100.00% |
| Profit | -$21.9M | -$9.5M | -130.92% |
| Profit per share | -$1.52 | -$0.86 | -76.74% |
| Free Cash Flow | -$2.7M | -$9.8M | +72.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We made significant progress during the second quarter, completing our pre-NDA meeting with FDA and initiating the rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Therapeutics Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Palvella Therapeutics, Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Palvella Therapeutics, Inc. has no earnings call transcript available.